“Tailored-to-You”: Public engagement and the political legitimation of precision medicine

Perspectives in Biology and Medicine

Volumn 59, Issue 2, 2016, Pages 172-188

  Blasimme, Alessandro ^a   Vayena, Effy ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012980087     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2017.0002     Document Type: Article

References (42)

1. Bayer, R., and S. Galea. 2015. “Public Health in the Precision-Medicine Era.” N Engl J Med 373 (6): 499–501. doi:10.1056/NEJMp1506241.
2. Biomarkers Definitions Working Group. 2001. “Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework.” Clin Pharmacol Ther 69 (3): 89–95. doi:10.1067/mcp.2001.113989.
3. Blasimme, A. and E. Vayena. 2016. “Becoming Partners, Retaining Autonomy: Ethical Considerations on the Development of Precision Medicine.” BMC Medical Ethics 17:67.
4. Chase, D. 2016. “Patient Engagement Is the Blockbuster Drug of the Century.” Forbes, Sept. 9. http://www.forbes.com/sites/davechase/2012/09/09/patient-engagement-is-the-blockbuster-drug-of-the-century/.
5. Chin, L., J. N. Andersen, and P. A. Futreal. 2011. “Cancer Genomics: From Discovery Science to Personalized Medicine.” Nat Med 17 (3): 297–303.
6. Christensen, C. M., J. H. Grossman, and J. Hwang. 2009. The Innovator’s Prescription: A Disruptive Solution for Health Care. New York: McGraw-Hill.
7. Collins, F. S., and H. Varmus. “A New Initiative on Precision Medicine.” N Engl J Med 37 (9): 793–95.
8. Evans, W. E., and M. V. Relling. 1999. “Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics.” Science 286 (5439): 487–91.
9. Evans, W. E., and M. V. Relling. 2004. “Moving Towards Individualized Medicine with Pharmacogenomics.” Nature 429: 464–68.
10. Flores, M., et al. 2013. “P4 Medicine: How Systems Medicine Will Transform the Healthcare Sector and Society.” Pers Med 10 (6): 565–76.
11. Gardiner, S. J., and E. J. Begg. 2006. “Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice.” Pharmacol Rev 58 (3): 521–90.
12. Ginsburg, G. S., and J. J. McCarthy. 2001. “Personalized Medicine: Revolutionizing Drug Discovery and Patient Care.” Trends Biotechnol 19 (12): 491–96. doi:10.1016/S0167-7799(01)01814-5.
13. Ginsburg, G. S., and H. F. Willard. 2009. “Genomic and Personalized Medicine: Foundations and Applications.” Transl Res 154 (6): 277–87.
14. Gonzalez, F. J. 1988. “The Molecular Biology of Cytochrome P450s.” Pharmacol Rev 40 (4): 243–88.
15. Hamburg, M. A., and F. S. Collins. 2010. “The Path to Personalized Medicine.” N Engl J Med 363 (4): 301–4.
16. Hawgood, S., et al. 2015. “Precision Medicine: Beyond the Inflection Point.” Sci Transl Med 7 (300): 300ps17. doi:10.1126/scitranslmed.aaa9970.
17. Hood, L., and M. Flores. 2012. “A Personal View on Systems Medicine and the Emergence of Proactive P4 Medicine: Predictive, Preventive, Personalized and Participatory.” New Biotechnol 29 (6): 613–24.
18. Hood, L., and S. H. Friend. 2011. “Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine.” Nat Rev Clin Oncol 8 (3): 184–87.
19. Irwin, A. 2006. “The Politics of Talk Coming to Terms with the ‘New’ Scientific Governance.” Soc Stud Sci 36 (2): 299–320. doi:10.1177/0306312706053350.
20. Jasanoff, S. 2004. “Ordering Knowledge, Ordering Society.” In States of Knowledge: The Co-Production of Science and the Social Order, ed. S. Jasanoff, 13–45. London: Routledge.
21. Jones, D. S. 2013. “The Prospects of Personalized Medicine.” In Genetic Explanation: Sense and Nonsense, 147–70. Cambridge: Harvard University Press.
22. Juengst, E. T., M. A. Flatt, and R. A. Settersten. 2012. “Personalized Genomic Medicine and the Rhetoric of Empowerment.” Hastings Cent Rep 42 (5): 34–40.
23. Kaye, J., et al. 2012. “From Patients to Partners: Participant-Centric Initiatives in Biomedical Research.” Nat Rev Genet 13 (5): 371–76.
24. Kitano, H. 2002. “Systems Biology: A Brief Overview.” Science 295 (5560): 1662–64.
25. Meyer, U. A. 2000. “Pharmacogenetics and Adverse Drug Reactions.” Lancet 356 (9242): 1667–71.
26. National Research Council. (2011). Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press.
27. Nicholson, J. K. 2006. “Global Systems Biology, Personalized Medicine and Molecular Epidemiology.” Mol Syst Biol 2 (1). doi:10.1038/msb4100095.
28. Prainsack, B., and E. Vayena. 2013. “Beyond the Clinic: ‘Direct-to-Consumer’ Genomic Profiling Services and Pharmacogenomics.” Pharmacogenomics 14 (4): 403–12.
29. Precision Medicine Initiative (PMI) Working Group. 2015. The Precision Medicine Cohort Program: Building a Research Foundation for 21st Century Medicine. NIH. http://acd.od.nih.gov/reports/DRAFT-PMI-WG-Report-9-11-2015-508.pdf.
30. Roses, A. D. 2000. “Pharmacogenetics and the Practice of Medicine.” Nature 405 (6788): 857–65.
31. Roses, A. D. 2004. “Pharmacogenetics and Drug Development: The Path to Safer and More Effective Drugs.” Nat Rev Genet 5 (9): 645–56.
32. Solomon, M. Z., M. K. Gusmano, and K. J. Maschke. 2016. “The Ethical Imperative and Moral Challenges of Engaging Patients and the Public with Evidence.” Health Aff (Millwood) 35 (4): 583–89. doi:10.1377/hlthaff.2015.1392.
33. Steele, F. R. 2009. “Personalized Medicine: Something Old, Something New.” Pers Med 6 (1): 1–5.
34. Terry, S. F., and P. F. Terry. 2011. “Power to the People: Participant Ownership of Clinical Trial Data.” Sci Transl Med 3 (69): 69cm3.
35. U.S. Food and Drug Administration (FDA). 2016. Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
36. Vayena, E. 2014. “Direct-to-Consumer Genomics on the Scales of Autonomy.” J Med Ethics 41 (4): 310–14. doi:10.1136/medethics-2014-102026.
37. Weston, A. D., and L. Hood. 2004. “Systems Biology, Proteomics, and the Future of Health Care: Toward Predictive, Preventative, and Personalized Medicine.” J Proteome Res 3 (2): 179–96.
38. Whirl-Carrillo, M., et al. 2012. “Pharmacogenomics Knowledge for Personalized Medicine.” Clin Pharmacol Ther 92 (4): 414–17. doi:10.1038/clpt.2012.96.
39. White House. 2015. Fact Sheet: President Obama’s Precision Medicine Initiative. https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-presi-dent-obama-s-precision-medicine-initiative.
40. White House. 2015. Privacy and Trust Principles for the President’s Precision Medicine Initiative. https://www.whitehouse.gov/sites/default/files/microsites/finalpmipriva-cyandtrustprinciples.pdf.
41. White House. 2015. Remarks by the President on Precision Medicine. https://www. hitehouse.gov/the-press-office/2015/01/30/remarks-president-precision-medicine.
42. White House. 2016. Remarks of the President in Precision Medicine Panel Discussion. 2016. https://www.whitehouse.gov/the-press-office/2016/02/25/remarks-president-precision-medicine-panel-discussion.